ACRV.US Acrivon Therapeutics, Inc. Common Stock

Healthcare Biotechnology USA Stocks
1.46 USD
Close of Nov 12, 2026
1.27 3.56
Market cap
USD 62.6M
P/E
-
P/B
0.78x
ROE
-85.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is ACRV.US undervalued?

Graham number

The Graham number of Acrivon Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Acrivon Therapeutics, Inc. Common Stock fundamental analysis

No fundamental analysis for Acrivon Therapeutics, Inc. Common Stock yet.

Acrivon Therapeutics, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Acrivon Therapeutics, Inc. Common Stock

Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients…

Full company profile